Dr Timon Vandamme

Go Back

Medical Oncologist

  • University Hospital Antwerp
  • location Belgium

Timon Vandamme is a Senior Consultant in digestive and neuroendocrine oncology at the Antwerp University Hospital. As a clinician-researcher, he is performing research in circulating cell-free DNA (ccfDNA) in digestive and neuroendocrine neoplasms.

 

Dr Vandamme obtained a joint PhD at the University of Antwerp, Belgium and the Erasmus MC, the Netherlands, on preclinical and translation evaluation of everolimus resistance and pancreatic NET genomics. His PhD project has led to multiple publications in peer-reviewed journals and received numerous awards, both national and international. Currently, he is holder of a Senior Clinical Investigator (FKM) grant of the Fonds Wetenschappelijk Onderzoek (FWO) at the University of Antwerp.

 

Furthermore, he is the Principal Investigator (PI) of > 10 trials at the University Hospital Antwerp, both industry-sponsored and academic trials. He is promotor of four PhD students and mentor of two additional PhD students. He has authored numerous papers outside his PhD in journals such as Clinical Cancer Research and Lancet Oncology. He has peer-reviewed for different high-impact journals and is a member of the editorial board of Endocrine-Related Cancer.

He is currently acting secretary of the Dutch Belgian Neuroendocrine Tumor Society (DBNETS) and co-opted board member of the Belgian Group of Digestive Oncology (BGDO).

 

Dr Timon Vandamme has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Programmes developed by Dr Timon Vandamme

video Video

Episode

1

of 4

episode
Oncology 
Treatment Options for HCC Patients Not Eligible for or Progressed on Immunotherapy – Episode 1

Reviewing the outcomes in HCC with 1st line immunotherapy

Experts
Prof. Michel Ducreux, Dr Timon Vandamme, Asst. Prof. Changhoon Yoo
Endorsed by
Digestive Cancers Europe
  • clock 24 MIN
  • calendar Jun 2023

Educational programme supported by an Independent Educational Grant from Bayer
video Video

Episode

2

of 4

episode
Oncology 
Treatment Options for HCC Patients Not Eligible for or Progressed on Immunotherapy – Episode 2

Patients with advanced HCC not eligible for IO in 1st line

Experts
Prof. Michel Ducreux, Dr Timon Vandamme, Asst. Prof. Changhoon Yoo
Endorsed by
Digestive Cancers Europe
  • clock 15 MIN
  • calendar Jun 2023

Educational programme supported by an Independent Educational Grant from Bayer
video Video

Episode

3

of 4

episode
Oncology 
Treatment Options for HCC Patients Not Eligible for or Progressed on Immunotherapy – Episode 3

Overview of 2nd line treatment options in advanced HCC

Experts
Prof. Michel Ducreux, Dr Timon Vandamme, Asst. Prof. Changhoon Yoo
Endorsed by
Digestive Cancers Europe
  • clock 14 MIN
  • calendar Jun 2023

Educational programme supported by an Independent Educational Grant from Bayer
video Video

Episode

4

of 4

episode
Oncology 
Treatment Options for HCC Patients Not Eligible for or Progressed on Immunotherapy – Episode 4

Panel Discussion and Summary

Experts
Prof. Michel Ducreux, Dr Timon Vandamme, Asst. Prof. Changhoon Yoo
Endorsed by
Digestive Cancers Europe
  • download Downloadable
    Resources
  • clock 15 MIN
  • calendar Jun 2023

Educational programme supported by an Independent Educational Grant from Bayer